LifeScience Antibody Drug Conjugates
Akeso Receives IND Approval in China for AK139, the First IL-4Rα/ST2 Bispecific Antibody
Akeso, Inc. is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (...
February 14, 2025 | News
DAAN Biotherapeutics and LigaChem Biosciences Forge Exclusive Licensing Deal to Advance ADC Development
DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, has signed an exclusive licensi...
February 14, 2025 | News
OnCusp Therapeutics Secures FDA Fast Track Designation for CUSP06 in Platinum-Resistant Ovarian Cancer
OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validat...
February 13, 2025 | News
China's BioRay Secures NMPA Nod for Clinical Trials of BR111, a First-in-Class Anti-ROR1 ADC
BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application f...
February 11, 2025 | News
GI Innovation and LaNova Medicines Join Forces for Breakthrough Pancreatic Cancer Combination Therapy
GI Innovation (KQ:358570) announced that it signed a Memorandum of Understanding (MOU) with LaNova Medicines (LaNova) for the development o...
January 23, 2025 | News
Lepu Biopharma Partners with ArriVent BioPharma for Global Development of MRG007, a Promising ADC for GI Cancers
Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) announced that it has entered into an exclusive licensing agreement with ArriVent BioPharma, Inc.&...
January 23, 2025 | News
InnoCare Pharma, KeyMed Biosciences, and Prolium Bioscience Partner on $520M Global Licensing Deal for CD20xCD3 Bispecific Antibody
InnoCare Pharma and KeyMed Biosciences announced that the two companies, together with their joint venture, have jointly entered into an exclusive li...
January 21, 2025 | News
Axcynsis Therapeutics Secures FDA Clearance for First ADC Program Utilizing AxcynDOT™ Technology
AT03-65 is the first program utilizing AxcynDOT™, a proprietary payload with a differentiated mechanism of action, to enter clinical d...
January 15, 2025 | News
Kelun-Biotech and Harbour BioMed Ink $970 Million Licensing Deal with Windward Bio for Anti-TSLP Antibody
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company and HBM Holdings Limited ("Harbour BioMed") (togeth...
January 13, 2025 | News
Global Frenzy for TCE Bispecific Antibodies: Billion-Dollar Deals Propel Chinese Biotech to the Forefront
The trading of TCE (T Cell Engager) bispecific antibodies remains hot, and multinational pharmaceutical companies (MNCs) are still placing orders frantical...
January 10, 2025 | News
Samsung Biologics and LigaChem Biosciences Partner to Advance ADC Therapies with New Dedicated Facility
Samsung Biologics to offer ADC services at new dedicated facility Extended collaboration reflects successful partnership and expertise Samsung Biolog...
January 09, 2025 | News
Biocytogen and Acepodia Join Forces to Advance Precision Oncology with Dual-Payload Bispecific ADCs
Collaboration initiates development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs) Biocytogen’s RenLite® meets Acepodia’s...
January 08, 2025 | News
Radiopharm and Lantheus Join Forces to Advance Radiopharmaceutical Clinical Development in Australia
RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial collaboration will focus on a Phase 1 imaging t...
December 31, 2024 | News
BeiGene Exercises Exclusive Option for DualityBio's B7H4 ADC, Paving the Way for Global Development
Duality Biologics ("DualityBio") announced that, BeiGene. Ltd. has exercised its exclusive option for the B7H4 antibody-drug conjugate (ADC) DB1312/BG-C907...
December 31, 2024 | News
Most Read
- Pioneering Precision: Top 15 Clinical and Lab Diagnostic Companies to Watch in 2025
- 2025 Pharma and Medical Device Trends for Manufacturing Leaders
- 25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
- James Park Joins South Korean LOTTE BIOLOGICS as New CEO to Lead Global Expansion
- Australia Takes the Lead: Moderna Opens Southern Hemisphere’s First mRNA Manufacturing Facility in Victoria
- Eli Lilly Announces $3 Billion Expansion in Wisconsin to Boost Global Medicine Production
- Ngee Ann Polytechnic Partners with Merck Singapore to Elevate Biopharmaceutical Education
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Life Sciences CEOs Bet Big on AI and Workforce Growth Despite Economic and Industry Headwinds
News
